MRC and AstraZeneca Scoop Prestigious SCRIP Award
News Dec 04, 2012
The AZ-MRC alliance broke new ground in the way industry collaborates with academia and government to share knowledge and discover and develop new drugs.
Clive Morris, AstraZeneca Vice President, New Opportunities iMed, said:
“We are deeply honoured that our alliance with the MRC has been singled out for its innovative character. This is especially meaningful because our alliance with the MRC has played a leading role in inspiring a new era of collaboration and open innovation in the industry.”
Dr Chris Watkins, Head of Translational Research and Industry Liaison at the MRC, who accepted the award, said:
"It's been an absolute pleasure to work with AstraZeneca throughout our ground-breaking compound collaboration and we feel we've made a real step forward in the way we collaborate with industry. We were really pleased with the quality of science we funded through the partnership and to have this all recognised by a prestigious SCRIP award is the icing on the cake, we're delighted to have won."
SCRIP is one of the world’s leading pharmaceutical and biotech news organisations and its ‘Best Partnership Alliance’ award recognises the importance of partnerships involving pharmaceutical and/or biotech companies in developing novel therapeutics.
The ceremony, which took place on 28 November at London’s Lancaster Hotel, rewarded excellence over the whole range of industry activities, from pharma, biotech and those companies that support them.
The AZ-MRC alliance, in which 22 previously studied AstraZeneca compounds were made available to academic researchers, was announced in December 2011. Since then, the MRC and AstraZeneca have announced £7 million funding for 15 research projects involving those compounds.
Cow Antibodies Yield Important Clues For Developing A Broadly Effective AIDS VaccineNews
The unexpected animal model is providing clues for important questions at a moment when new energy has infused HIV vaccine research.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018